Ribupatide: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข3 clinical studies cited
- โขOverall evidence level: moderate
- โข6 research gaps identified
Research Studies
Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Obese Adults - A Phase 2 Trial
Hengrui Pharma investigators (2024) โข Diabetes (ADA Poster)
Phase 2 trial of injectable HRS9531 (8 mg once weekly) in adults with obesity or overweight without type 2 diabetes over 36 weeks. The 8 mg dose achieved 22.8% mean weight loss (21.1% placebo-adjusted), with 59% of participants achieving 20% or more weight loss.
Key Findings
- 22.8% mean weight loss at 36 weeks (8 mg injectable)
- 21.1% placebo-adjusted weight loss
- 59% of participants achieved 20% or more weight loss
- No weight loss plateau observed at end of treatment
Limitations: Abstract/poster presentation; full publication pending; limited safety data disclosed; single ethnic population (China)
Phase 2 Obesity Trial of Oral Ribupatide in Chinese Adults
Hengrui Pharma and Kailera Therapeutics investigators (2026) โข Press release (Globe Newswire)
Phase 2 trial (HRS9531-T-201) of once-daily oral ribupatide in 166 Chinese adults with obesity (BMI 28 or more) without type 2 diabetes over 26 weeks. Doses of 10, 25, and 50 mg were evaluated.
Key Findings
- Mean weight loss of 12.1% at 26 weeks with the 25 mg and 50 mg oral doses
- 38.6% of participants achieved 15% or more weight loss (highest dose group)
- No weight loss plateau observed at 26 weeks
- Oral GLP-1/GIP dual agonist formulation demonstrated clinically meaningful weight loss
Limitations: Press release data only; full trial results not yet peer-reviewed; 26-week duration; Chinese population only
Phase 2 Clinical Trial of HRS9531 in Adults with Obesity Without Diabetes - Up to 52 Weeks (ADA 2025)
Hengrui Pharma investigators (2025) โข ADA Scientific Sessions
Extended Phase 2 data presented at ADA 2025, showing continued weight loss with HRS9531 through 52 weeks of treatment in Chinese adults with obesity.
Key Findings
- Continued weight loss through 52 weeks without plateau
- Favorable safety profile consistent with GLP-1/GIP class
Limitations: Conference presentation; details of extended treatment outcomes not fully disclosed in publicly available sources
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
0View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขNo peer-reviewed full publications for the Phase 2 injectable results; primary data from conference abstracts and press releases
- โขNo cardiovascular outcomes data; no CVOT planned or disclosed
- โขLimited data from non-Chinese populations; global Phase 2 oral trial planned for 2026
- โขNo head-to-head comparison with tirzepatide or semaglutide
- โขLong-term safety and efficacy data beyond 52 weeks limited
- โขOral formulation bioavailability and food effect data not disclosed
Research Overview#
Ribupatide (HRS9531/KAI-9531) has been evaluated in Phase 2 clinical trials for both injectable and oral formulations, primarily in Chinese populations. The evidence base is growing and supported by randomized controlled trials, though much of the data remains in the form of conference abstracts and press releases rather than peer-reviewed full publications.
The weight loss efficacy demonstrated in Phase 2 is among the highest reported for any anti-obesity agent: 21.1% placebo-adjusted weight loss with the injectable formulation at 36 weeks, with no plateau observed. The oral formulation also showed competitive results at 12.1% weight loss at 26 weeks.
Phase 2 Injectable Trial#
The pivotal Phase 2 data were presented at ADA 2024. The trial evaluated once-weekly subcutaneous HRS9531 at the 8 mg dose in adults with obesity or overweight without type 2 diabetes. Over 36 weeks, participants achieved:
- Mean weight loss of 22.8% (21.1% placebo-adjusted)
- 59% of HRS9531-treated participants achieved weight loss of 20% or greater
- No evidence of weight loss plateau at end of treatment, suggesting continued efficacy with longer treatment
These results position ribupatide's injectable formulation among the most efficacious anti-obesity agents in clinical development, comparable to the highest doses of tirzepatide.
Phase 2 Oral Trial#
The oral Phase 2 trial (HRS9531-T-201) was conducted in China and enrolled 166 adults with obesity (BMI 28 or above) without diabetes, randomized to 10 mg, 25 mg, or 50 mg oral ribupatide daily or placebo for 26 weeks.
Results announced in February 2026:
- 10 mg: 6.9% mean weight loss
- 25 mg: 12.1% mean weight loss
- 50 mg: 12.1% mean weight loss
- Placebo: 2.3% mean weight loss
Up to 38.6% of participants taking oral ribupatide achieved at least 15% weight loss. No plateau was observed at 26 weeks.
Phase 3 Development#
KaiNETIC Global Program (Injectable)#
Kailera Therapeutics has initiated the KaiNETIC global Phase 3 program for injectable ribupatide, with first participants randomized. This represents the global pivotal program for regulatory submissions outside China.
Phase 3 China Programs#
Hengrui has completed Phase 3 obesity trials in China for the injectable formulation and is advancing oral ribupatide to Phase 3 in China based on the positive Phase 2 data. Additional Phase 3 data from China have been reported showing continued weight loss benefits.
Evidence Quality Assessment#
| Evidence Criterion | Assessment | Details |
|---|---|---|
| Study design | RCTs | Double-blind, placebo-controlled |
| Sample size | Moderate | Phase 2 adequate; Phase 3 enrollment ongoing |
| Publication status | Mostly press releases/abstracts | Full publications pending |
| Population diversity | Limited | Primarily Chinese populations to date |
| Active comparator | Not available | No head-to-head data |
| CV outcomes | Not studied | No CVOT |
| Dual formulations | Yes | Both injectable and oral in trials |
Key Research Gaps#
-
Publication status: Most data from press releases and conference abstracts rather than peer-reviewed publications, limiting critical evaluation.
-
Population generalizability: Phase 2 data primarily from Chinese populations. Global data from KaiNETIC Phase 3 will address this.
-
Cardiovascular outcomes: No CVOT data available, unlike semaglutide (SELECT) which demonstrated 20% MACE reduction.
-
Head-to-head comparisons: No direct comparison with tirzepatide, despite both being dual GLP-1/GIP agonists.
-
Oral bioavailability: Specific oral bioavailability, food effects, and absorption enhancement technology not publicly disclosed.
Related Reading#
Frequently Asked Questions About Ribupatide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.